Silihan lan utang jangka dawa perusahaan: Gyre Corp (GYRE)

This price chart on the GURU.Markets platform illustrates the price action of Gyre Therapeutics, Inc. (GYRE), whose long-term debt stands at 0.00. High barriers to entry in the sector are driven by development complexity and strict regulatory oversight. Gyre Therapeutics, Inc. (GYRE) dominates the Asian market through exclusive patents, while its strategy relies on the systematic expansion of its portfolio of innovative drugs for the treatment of fibrosis.

GYRE Utang jangka dawa perusahaan Gyre Therapeutics, Inc. (21.02.2024 - 01.11.2026)

Ringkesan rincian data analitis Gyre Corp (GYRE)

- rega pasar lan target rega analis:

Rega saham gyretx.com|GYRE - Bagan rega target

- indikator kapitalisasi bursa perusahaan:

Nilai pasar Gyre Therapeutics|GYRE - Nilai Total Perusahaan

- informasi kapitalisasi buku:

Nilai Akuntansi saben Saham Gyre Therapeutics|GYRE - Kapitalisasi Buku|Rasio Kapitalisasi Pasar marang Nilai Buku gyretx.com|GYRE - Gunggung Aset Perusahaan

- data tingkat utang lan likuiditas finansial:

Rasio Kabeh Utang marang Dana Pribadi Gyre Therapeutics, Inc.|GYRE - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas Gyre Therapeutics Corp.|GYRE - Gunggung utang perusahaan|Utang-utang marang aset resik Gyre Therapeutics|GYRE - Kewajiban jangka dawa perusahaan|Utang jangka cendhak perusahaan Gyre Therapeutics|Likuiditas darurat gyretx.com

- data bathi lan kelipatan valuasi:

GYRE - Bathi resik perusahaan

Ringkesan analitik perusahaan:GYRE gyretx.com

This indicator aggregates all liabilities with a maturity of more than one year, measuring the issuer's long-term credit burden and financial stability. By analyzing the current level of long-term debt, an investor can assess the liquidity risks of Gyre Therapeutics, Inc. (GYRE) when financing costly clinical trials and undergoing regulatory reviews in the US and China.

Analisis pesaing Gyre Therapeutics, Inc.